Follow
Kevin Outterson
Title
Cited by
Cited by
Year
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
E Tacconelli, E Carrara, A Savoldi, S Harbarth, M Mendelson, DL Monnet, ...
The Lancet infectious diseases 18 (3), 318-327, 2018
52102018
The global preclinical antibacterial pipeline
U Theuretzbacher, K Outterson, A Engel, A Karlén
Nature Reviews Microbiology 18 (5), 275-285, 2020
5932020
Antibiotic development—economic, regulatory and societal challenges
C Årdal, M Balasegaram, R Laxminarayan, D McAdams, K Outterson, ...
Nature Reviews Microbiology 18 (5), 267-274, 2020
3372020
Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets
K Outterson
Yale J. Health Pol’y L. & Ethics 5, 193, 197, 2005
2612005
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later
R Laxminarayan, T Van Boeckel, I Frost, S Kariuki, EA Khan, ...
The Lancet Infectious Diseases 20 (4), e51-e60, 2020
2462020
International cooperation to improve access to and sustain effectiveness of antimicrobials
C Årdal, K Outterson, SJ Hoffman, A Ghafur, M Sharland, N Ranganathan, ...
The Lancet 387 (10015), 296-307, 2016
1822016
An international legal framework to address antimicrobial resistance
SJ Hoffman, K Outterson, JA Røttingen, O Cars, C Clift, Z Rizvi, F Rotberg, ...
Bulletin of the World Health Organization 93, 66-66, 2015
1432015
The ethics of poverty tourism
E Selinger, K Outterson
Boston University School of Law Working Paper, 2009
137*2009
Plunging into Endless Difficulties: Medicaid and Coercion in National Federation of Independent Business v. Sebelius
N Huberfeld, EW Leonard, K Outterson
BUL Rev. 93, 1, 2013
130*2013
Progress in the fight against multidrug-resistant bacteria? A review of US Food and Drug Administration–approved antibiotics, 2010–2015
D Deak, K Outterson, JH Powers, AS Kesselheim
Annals of internal medicine 165 (5), 363-372, 2016
1202016
Antibiotic research and development: business as usual?
S Harbarth, U Theuretzbacher, J Hackett, Drive-AB Consortium, ...
Journal of Antimicrobial Chemotherapy 70 (6), 1604-1607, 2015
1182015
Repairing the broken market for antibiotic innovation
K Outterson, JH Powers, GW Daniel, MB McClellan
Health affairs 34 (2), 277-285, 2015
1102015
Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward
AK Nanayakkara, HW Boucher, VG Fowler Jr, A Jezek, K Outterson, ...
CA: a cancer journal for clinicians 71 (6), 488-504, 2021
1092021
Towards new business models for R&D for novel antibiotics
AD So, N Gupta, SK Brahmachari, I Chopra, B Munos, C Nathan, ...
Drug Resistance Updates, 2011
1012011
Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Intellectual Property Law, The
K Outterson
U. Pitt. L. Rev. 67, 67, 2005
912005
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach
JH Rex, K Outterson
The Lancet Infectious Diseases 16 (4), 500-505, 2016
902016
What will it take to address the global threat of antibiotic resistance?
SJ Hoffman, K Outterson
Journal of Law, Medicine & Ethics 43 (S3), 6-11, 2015
882015
Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals
AS Kesselheim, K Outterson
Health Affairs 29 (9), 1689-1696, 2010
872010
Will longer antimicrobial patents improve global public health?
K Outterson, JB Samora, K Keller-Cuda
The Lancet infectious diseases 7 (8), 559-566, 2007
822007
Patent buy-outs for global disease innovations for low-and middle-income countries
K Outterson
Am. JL & Med. 32, 159, 2006
772006
The system can't perform the operation now. Try again later.
Articles 1–20